Using immunonutrition to enhance immunotherapy effectiveness in lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the impact of early systematic provision of oral nutritional supplements enriched with immunonutrients for patients with metastatic non-small cell lung cancer who are undergoing immunotherapy. Participants will receive nutritional counseling alongside their treatment to assess whether this approach improves treatment efficacy. The study aims to provide insights into the role of nutrition in cancer therapy, particularly in enhancing the immune response during treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed histological diagnosis of metastatic non-small cell lung cancer (both squamous and non-squamous histology);
* First-line treatment with immunotherapy (alone or in combination with chemotherapy) for metastatic disease by investigators' choice within the framework of good clinical practice and in agreement with current guidelines;
* Will to participate by providing written informed consent;
* Availability to administer oral supplements and immunotherapy with or without chemotherapy;
* Eastern Cooperative Oncology Group Performance Status ≤ 2;
* Life expectancy ≥ 6 months.

Exclusion Criteria:

* Age \< 18 years;
* Inability to sign an informed consent;
* Indication to or ongoing artificial nutrition support (totally compromised spontaneous food-intake) and incapacity or unavailability to consume oral nutritional supplements

Where it's running

• Fondazione IRCCS Policlinico San Matteo
  Pavia, Italy Recruiting

Study contacts

• Principal investigator: Riccardo Caccialanza, MD — Fondazione IRCCS Policlinico San Matteo
• Study coordinator: Riccardo Caccialanza, MD
• Email: r.caccialanza@smatteo.pv.it
• Phone: 0382501615

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term clinical and tissue data collection for people with thoracic cancers

  This project will collect medical records, imaging, quality-of-life information, and tissue/blood samples over time from adults with thoracic cancers to try to find factors that predict outcomes.

  Recruiting at 11 sites Dutch Society of Physicians for Pulmonology and Tuberculosis · Ede, Gelderland and 22 other locations · NCT06996249

• Analyzing the effects of low-dose nivolumab with chemotherapy for lung cancer treatment

  This study is testing if a low dose of nivolumab combined with chemotherapy can help people with early-stage non-small cell lung cancer respond better to treatment.

  Recruiting Phase 2 Fundação Faculdade Regional de Medicina de São José do Rio Preto · São José do Rio Preto, São Paulo · NCT06667154

• Personalized toripalimab therapy for lung cancer based on ctDNA analysis

  This study is testing if using blood tests to check for leftover cancer DNA can help decide if lung cancer patients should get extra treatment with toripalimab after their initial therapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06426511

• Integrative platform for personalized lung cancer care using AI

  This study is trying to create a smart tool that helps doctors predict how well immunotherapy will work for people with non-small cell lung cancer, so they can make better treatment choices.

  Recruiting at 4 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Chicago, Illinois and 3 other locations · NCT05537922

• Reduced frequency of pembrolizumab treatment for advanced lung cancer

  This study is testing if giving pembrolizumab treatment for advanced lung cancer less often can still work well while making life easier for patients.

  Recruiting at 33 sites Phase 3 Imperial College London · Bournemouth and 36 other locations · NCT05085028

• Combining tocilizumab and atezolizumab for advanced lung cancer after previous treatments

  This study is testing if combining two medications, tocilizumab and atezolizumab, can help adults with advanced lung cancer that hasn't improved with previous treatments.

  Recruiting Phase 1/2 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT04691817

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.